| 1. |
Tallouzi MO, Moore DJ, Calvert M, et al. The effectiveness of pharmacological agents for the treatment of uveitic macular oedema (UMO): a systematic review protocol[J]. Systematic Reviews, 2016, 5: 29. DOI: 10.1186/s13643-016-0203-y.
|
| 2. |
姜允彬, 王泓. 难治性葡萄膜炎黄斑水肿的治疗进展[J]. 中华眼底病杂志, 2017, 33(1): 96-99. DOI:10.3760/cma.j.issn.1005-1015.2017.01.031.Jiang YB, Wang H. Advances in treatment of refractory uveitic macular edema[J]. Chin J Ocul Fundus Dis, 2017, 33(1): 96-99. DOI:10.3760/cma.j.issn.1005-1015.2017.01.031.
|
| 3. |
Wang Q, Li T, Wu Z, et al. Novel VEGF decoy receptor fusion protein conbercept targeting multiple VEGF isoforms provide remarkable anti-angiogenesis effect in vivo[J/OL]. PLoS One, 2013, 8(8): 70544[2013-08-12]. http://dx.plos.org/10.1371/journal.pone.0070544. DOI: 10.1371/journal.pone.0070544.
|
| 4. |
Lu X, Sun X. Profile of conbercept in the treatment of neovascular age-related macular degeneration[J]. Drug Des Devel Ther, 2015, 9: 2311-2320. DOI: 10.2147/DDDT.S67536.
|
| 5. |
Al-Dhibi H, Hamade IH, Al-Halafi A, et al. The effects of intravitreal bevacizumab in infectious and noninfectious uveitic macular edema[J/OL]. J Ophthalmol, 2014, 2014: 729465[2014-07-21]. https://dx.doi.org/10.1155/2014/729465. DOI: 10.1155/2014/729465.
|
| 6. |
Li X, Xu G, Wang Y, et al. Safety and efficacy of conbercept in neovascular age-related macular degeneration: results from a 12-month randomized phase 2 study: AURORA study[J]. Ophthalmology, 2014, 121(9): 1740-1747. DOI: 10.1016/j.ophtha.2014.03.026.
|
| 7. |
Zhang M, Zhang J, Yan M, et al. A phase 1 study of KH902, a vascular endothelial growth factor receptor decoy, for exudative age-related macular degeneration[J]. Ophthalmology, 2011, 118(4): 672-678. DOI: 10.1016/j.ophtha.2010.08.008.
|
| 8. |
Jabs DA, Nussenblatt RB, Rosenbaum JT. Standardization of uveitis nomenclature for reporting clinical data: results of the first international workshop[J]. Am J Ophthalmol, 2005, 140(3): 509-516.
|
| 9. |
Singer MA, Awh CC, Sadda S, et al. HORIZON: an open-label extension trial of ranibizumab for choroidal neovascularization secondary to age-related macular degeneration[J]. Ophthalmology, 2012, 119(6): 1175-1183. DOI: 10.1016/j.ophtha.2011.12.016.
|
| 10. |
Acharya NR, Hong KC, Lee SM. Ranibizumab for refractory uveitis-related macular edema[J].Am J Ophthalmol, 2009, 148(2): 303-309. DOI: 10.1016/j.ajo.2009.03.028.
|
